Biotron Limited · ASX:BIT
Biotron — 2013 BIO International Convention
12 slides from Biotron's conference presentation, Apr 26, 2013
Slide 1: ASX cover letter: CEO Presentation at the 2013 BIO International Convention
Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au For personal use only Website: www.biotron.com.au 26 April 2013 The Manager Companies ASX Limited 20 Bridge Street Sydney NSW 2000 (12 pages by email) Dear Madam CEO PRESENTATION
Slide 2: About Biotron
About Biotron Biotron Limited is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need, with a major focus on HIV and HCV. The Company has BIT225 in clinical development for both HIV and HCV, and also has several earlier sta
Slide 3: Biotron Limited (ASX:BIT) Clinical Stage Antiviral Drug Development Company
BIOTRON LIMITED (ASX:BIT) For personal use only Clinical Stage An;viral Drug Development Company Michelle Miller CEO & Managing Director +61 (0) 412 313 329 mmiller@biotron.com.au
Slide 4: Forward Looking Statements
Forward Looking Statements For personal use only This presenta,on may contain forward-‐looking statements with respect to the financial condi,on, results and business achievements/performance of Biotron Limited and certain of the plans and objec,ves of its management. These statements are statements
Slide 5: Biotron Limited Overview
Biotron Limited Overview For personal use only • Clinical stage an,viral drug development company • Focus on developing novel small molecule drugs • Clinical programs for Hepa,,s C virus (HCV) and HIV • Earlier stage programs include Dengue and others • Headquartered in Sydney, Australia • Key recen
Slide 6: Biotron - Advanced Pipeline of Clinical Programs
Biotron -‐ Advanced Pipeline of Clinical Programs VIRAL For personal use only INDICATION DISCOVERY PRE-‐CLINICAL PHASE 1a PHASE 1b PHASE 2a PHASE 2b STATUS TARGET Ph 2a complete; HEP C p7 Ph 2b (3 mth dosing) scheduled for 4Q13 Ph 1b/2a HIV Vpu complete Ph 2 Hep C/HIV Vpu/p7 In progress Dengue M N
Slide 7: BIT225 and Hepatitis C
BIT225 and Hepa;;s C For personal use only • New inves,ga,onal oral drug for trea,ng HCV infec,on • First in class; targets p7 protein – essen,al for virus assembly and release • Preclinical studies – synergism with IFN/RBV and polymerase inhibitors • Three completed trials: § Phase Ia –Single dose
Slide 8: BIT225 HCV Phase Clinical Information
BIT225 HCV Phase 2 Clinical Informa;on For personal use only Median log reduc;on % Complete EVR % ETVR Treatment at 35 days (<50IU/ml at 12 weeks) (<50IU/ml at 48 weeks) 400 mg BIT225 + IFN/RBV -‐4.957 86 100 200 mg BIT225 + IFN/RBV -‐4.351 88 88 Placebo + IFN/RBV -‐3.649 63 75 • Clear demonstra,
Slide 9: BIT225 and HIV
BIT225 and HIV • BIT225 also has potent an,-‐HIV ac,vity For personal use only – Unique mode of ac,on targets HIV “hiding” in long-‐lived reservoir cells • Reservoirs are last of the holy grail in HIV * • No exis,ng drugs target this source of HIV in the body • Phase 2a trial of BIT225 in HIV-‐in
Slide 10: BIT225 - HIV / HCV Co-Infected Population
BIT225 -‐ HIV / HCV Co-‐Infected Popula;on • 25 – 40% of HIV-‐infected people in the USA are also HCV-‐infected For personal use only – Significantly worse prognosis than mono-‐infected pa,ents – US and European regulatory agencies have stated the need for new treatment strategies for this difficu
Slide 11: Biotron Programs Summary
Biotron Programs Summary • Documented need for new an,viral drugs For personal use only • Licensing space is very ac,ve • BIT225 has shown good clinical efficacy against both HCV and HIV • Poten;al to be used with new (DAA) or exis;ng classes of HCV drugs • Phase 2b, 3 month study in combina,on with I
Slide 12: Key Financials and Facts
Key Financials and Facts BIOTRON ASX Code LIMITED KEY FINANCIALS price BIT history chart Mr Michael Hoy BOARD AND MANAGEMENT Chairman For personal use only Recent Share Price (23 April 2013) A$0.11 Dr Michelle Miller CEO & Managing Director 52 Week High A$0.185 Dr Denis Wade Non-‐Execu;ve Director